DY2 Stock Chart & Stats
CHF9.87
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF9.87
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF7.02 - CHF11.46
Previous CloseN/A
Volume0.00
Average Volume (3M)100.00
Market Cap
CHF1.42B
Enterprise ValueCHF4.20B
Total Cash (Recent Filing)CHF239.00M
Total Debt (Recent Filing)CHF2.31B
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Oct 29, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares OutstandingN/A
10 Day Avg. Volume300
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF11.06Price Target Upside12.06% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)1.27
Revenue Forecast (FY)CHF2.98B
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationSustained positive operating cash flow and free cash flow give DENTSPLY SIRONA internal funding capacity while it executes its turnaround. Although cash generation is below earlier levels, ongoing conversion supports investment in products, commercial initiatives, and debt servicing over the coming quarters.
Resilient Core EconomicsA gross margin near 50% indicates that the company’s dental products and technologies retain meaningful underlying economics despite weaker demand and reported losses. Narrowing losses could provide a foundation for operating leverage if revenue stabilizes and efficiency initiatives gain traction.
Wellspect Product MomentumWellspect’s growth shows that DENTSPLY SIRONA can generate demand through product innovation and geographic expansion even while broader segments contract. Continued adoption of newer offerings can diversify growth, reinforce the company’s clinical portfolio, and support a more durable recovery.
Bears Say
Persistent Revenue DeclineMulti-year revenue contraction combined with a deeply negative TTM net margin indicates that the business has not yet restored durable top-line momentum or profitable scale. Continued losses can constrain reinvestment and make the turnaround more dependent on execution and demand recovery.
Elevated LeverageHigher leverage reduces financial flexibility while earnings remain weak, leaving less room to absorb operating setbacks or fund strategic investment internally. The debt burden also raises the importance of consistent cash generation and successful margin recovery for balance-sheet stabilization.
Broad Segment WeaknessWeakness across multiple product areas, especially OIS and SureSmile, suggests the revenue pressure is broader than a single isolated business line. Persistent volume declines could delay the return-to-growth plan, limit operating leverage, and prolong pressure on profitability through the next several quarters.
DENTSPLY SIRONA News
DY2 FAQ
What was DENTSPLY SIRONA Inc’s price range in the past 12 months?
DENTSPLY SIRONA Inc lowest stock price was CHF7.02 and its highest was CHF11.46 in the past 12 months.
What is DENTSPLY SIRONA Inc’s market cap?
DENTSPLY SIRONA Inc’s market cap is CHF1.42B.
When is DENTSPLY SIRONA Inc’s upcoming earnings report date?
DENTSPLY SIRONA Inc’s upcoming earnings report date is Oct 29, 2026 which is in 15 days.
How were DENTSPLY SIRONA Inc’s earnings last quarter?
DENTSPLY SIRONA Inc released its earnings results on Aug 06, 2026. The company reported CHF0.433 earnings per share for the quarter, beating the consensus estimate of CHF0.29 by CHF0.143.
Is DENTSPLY SIRONA Inc overvalued?
According to Wall Street analysts DENTSPLY SIRONA Inc’s price is currently Undervalued.
Does DENTSPLY SIRONA Inc pay dividends?
DENTSPLY SIRONA Inc does not currently pay dividends.
What is DENTSPLY SIRONA Inc’s EPS estimate?
DENTSPLY SIRONA Inc’s EPS estimate is 0.26.
How many shares outstanding does DENTSPLY SIRONA Inc have?
Currently, no data Available
What happened to DENTSPLY SIRONA Inc’s price movement after its last earnings report?
DENTSPLY SIRONA Inc reported an EPS of CHF0.433 in its last earnings report, beating expectations of CHF0.29. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DENTSPLY SIRONA Inc?
Currently, no hedge funds are holding shares in CH:DY2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DENTSPLY SIRONA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF11.06 (12.06% Upside)
CHF11.06 (12.06% Upside)
Blogger Sentiment
Neutral
CH:DY2 Sentiment 83%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.85%
12-Months-Change
Fundamentals
Return on Equity
-39.81%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
DENTSPLY SIRONA Inc
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
DY2 Company Deck
DY2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.View all CH:DY2 earnings summariesDY2 Net sales Breakdown
15.71% Equipment & Instruments
12.45% CAD/CAM
39.92% Essential Dental Solutions
6.17% Orthodontics
16.93% Implants & Prosthetics
8.83% Wellspect Healthcare
DY2 Stock 12 Month Forecast
Average Price Target
CHF11.06
▲(12.06% Upside)